ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting. The Annual Genera ...

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai on March 19-20, 2026 [1][2] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (Lu) or Lead-203 (Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with Lu can predict behavior with the therapeutic isotope Actinium-225 (Ac) [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner [3] - This feature enables the selection of the most suitable therapeutic isotope based on initial clinical data without restarting the entire drug discovery process, which is a significant advantage for tailoring treatments to patient needs [3] Group 3: Clinical Trials and Collaborations - The DLL3-targeted Pb-based Radio-DARPin candidate MP0712 is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, covering activities for Radio-DARPins with Ac as the therapeutic payload and Lu as the imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions, addressing limitations of traditional radioligand therapy such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while preserving the advantages of small protein formats, thus unlocking a broad range of tumor targets for targeted radiopharmaceuticals [7] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address, with proprietary programs in various stages of development [10]

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai [1][4] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (177Lu) and Lead-203 (203Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with 177Lu can predict behavior with the therapeutic isotope Actinium-225 (225Ac) and similarly for 203Pb with 212Pb [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner, which can be tailored to patient needs without restarting the drug development process [3] Group 3: Clinical Trials and Partnerships - The MP0712 candidate, which targets DLL3 and is co-developed with Orano Med, is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, focusing on 225Ac as a therapeutic payload and 177Lu as an imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes precisely to tumor lesions, addressing limitations of traditional radioligand therapy, such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while minimizing harm to healthy tissues, leveraging the unique properties of DARPins [9] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for challenging medical conditions, with proprietary programs in various stages of development and partnerships with leading pharmaceutical companies [10]

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations at AACR 2026: ...

Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical ...

Financial Performance - As of December 31, 2025, the company had cumulative losses of CHF 311.8 million, with a negative net result attributable to shareholders of CHF 61.7 million for the year ended December 31, 2025[38]. - The company has invested most of its resources in developing product candidates and has never generated any revenue from product sales since its inception in 2004[40]. - The company has incurred significant operating losses primarily due to research and development costs, with expectations of continued losses in future periods[39]. - The company anticipates that its existing cash and cash equivalents will fund operations into 2028, but this estimate is based on assumptions that may prove incorrect[46]. Funding and Capital Requirements - The company expects to incur significant additional funding needs to complete the development and commercialization of its product candidates, with a sales agreement in place for gross sales proceeds of up to $100.0 million[44]. - Future capital requirements will depend on various factors, including the ability to raise additional funds, which may be limited due to the company's status as a Swiss corporation[46]. - The company may need to relinquish rights to technologies or product candidates if it cannot secure necessary funding, which could adversely affect its business prospects[51]. Clinical Development and Regulatory Approval - All product candidates are in preclinical or various stages of clinical development, with no candidates having received marketing approval from the FDA or other regulatory authorities[66]. - The process of obtaining regulatory approval is lengthy and expensive, often taking many years and requiring substantial evidence from clinical trials[67]. - Clinical trials are subject to delays due to various factors, including regulatory approvals, patient recruitment, and compliance with protocols, which can significantly impact costs and timelines[58][61]. - The company faces risks associated with conducting clinical trials in multiple countries, including adherence to protocols and additional regulatory requirements[63][64]. - The company must demonstrate safety, purity, and efficacy through extensive preclinical studies and clinical trials to obtain regulatory approvals[67]. Risks and Challenges in Clinical Trials - The company may face delays in clinical trials and regulatory approvals due to health epidemics, which could adversely impact its business operations[47]. - Delays in clinical trials can harm the commercial prospects of product candidates and may allow competitors to bring products to market first[61]. - Positive results from early preclinical studies do not guarantee success in later stages of development or regulatory approval[70][71]. - Adverse side effects from product candidates could delay or prevent marketing approval, affecting the commercial profile and potential revenue[82]. - Patient enrollment in clinical trials is critical, and difficulties in recruitment could delay product development and approval[90]. Market and Competitive Landscape - The company faces significant competition from established pharmaceutical and biotechnology companies, which may limit commercial opportunities[89]. - Market acceptance of the company's products will depend on various factors, including physician and patient perceptions, reimbursement availability, and competitive advantages over alternative treatments[145]. - The company may face competition from biosimilars sooner than anticipated due to the Biologics Price Competition and Innovation Act, which allows for abbreviated approval pathways[149]. Regulatory Environment and Compliance - The company is subject to stringent U.S. and foreign data privacy laws, which could lead to significant penalties and operational disruptions if compliance is not maintained[188]. - The company faces significant civil, criminal, and administrative penalties if found in violation of healthcare laws and regulations[125]. - Compliance with manufacturing regulations requires significant resources, and failure to meet these requirements could lead to enforcement actions and adversely affect product supplies[220]. Intellectual Property and Patents - The company faces challenges in obtaining and maintaining patents and intellectual property rights, which are crucial for competitive advantage and commercial success[226]. - The patent prosecution process is expensive and complex, with uncertainty regarding the issuance and scope of patents, potentially impacting the company's market share[227]. - The validity and enforceability of the company's patent rights are uncertain, which could affect the commercial value of its technology[229]. Collaboration and Partnerships - The company is dependent on collaborative partners for the development and commercialization of its research programs and product candidates, which could adversely affect its business if these relationships are not maintained[212]. - The company currently has collaborative research relationships with institutions such as the University of Bern and Orano Med, and discussions for potential partnerships with various pharmaceutical companies are ongoing[213]. - The company faces significant competition in securing collaborative partners, which may impact its ability to negotiate timely and favorable agreements[215]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers (CMOs) for producing clinical drug supplies and lacks internal manufacturing capabilities, increasing risks associated with supply chain disruptions[218]. - The company relies on single-source unaffiliated third-party suppliers for certain raw materials, which poses a risk to production continuity if these suppliers fail to deliver[185]. - Manufacturing process failures could result in product defects, recalls, and insufficient inventory, adversely affecting the company's ability to supply approved products[183].

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range of isotopes ...

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, a new class of custom-built protein drugs [5] - The company will present at two upcoming investor conferences and release its full-year 2025 financial report on March 12, 2026 [1][4] Conference Details - Molecular Partners will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA from March 2-4, 2026, with CEO Patrick Amstutz scheduled for a fireside chat on March 2 [2] - The company will also attend the Leerink Partners Global Healthcare Conference in Miami, FL from March 9-11, 2026, where CEO Patrick Amstutz will have a fireside chat on March 9 [3] Financial Reporting - The full-year 2025 financial results will be announced on March 12, 2026, at 4:00 PM EDT [4]

Core Insights - Molecular Partners AG has entered into a partnership with Eckert & Ziegler to advance its Radio-DARPin therapeutics pipeline, focusing on imaging and therapeutic radio-isotopes, including Actinium-225 [1][2] Group 1: Partnership and Development - The agreement with Eckert & Ziegler will enhance the potential of Radio-DARPins for precise delivery of therapeutic alpha-emitting isotopes to tumors, including Actinium-225 and Lead-212 [2][3] - Eckert & Ziegler will provide a comprehensive range of services for the development of Radio-DARPins with Actinium-225 and Lutetium-177 payloads, utilizing its advanced laboratories [3] Group 2: Pipeline and Research - Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs, aiming to match vector and isotope properties with target and disease biology [4] - The company plans to present pre-clinical data on the suitability of Radio-DARPins with multiple isotopes at the Global Radiopharmaceuticals Development Summit in March 2026 [4] Group 3: Technology and Innovation - Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions while minimizing toxicity to healthy tissues, addressing historical limitations of radioligand therapy [6][7] - The proprietary Radio-DARPin platform incorporates half-life extension technologies and surface engineering approaches to enhance therapeutic efficacy [6][7] Group 4: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address [9] - The company has proprietary programs in various stages of pre-clinical and clinical development, alongside partnerships with leading pharmaceutical companies and academic centers [9]

Core Insights - The call discusses data presented at the Theranostics World Conference in South Africa regarding MP0712, a DLL3 targeting radiotherapeutic [2] - The data includes clinical imaging and dosimetry results from a named patient access program under South Africa's Section 21 of the Medicines and Related Substances Act [2] Company Information - The presentation is led by Seth Lewis, the Head of Investor Relations and Strategy, indicating a structured approach to investor communication [2] - The clinical study was supervised by Dr. Mike Sathekge, a prominent figure in Nuclear Medicine at the University of Pretoria and Steve Biko Academic Hospital [3]